An Open Label Multicenter Post Marketing Observational Study for the Evaluation of Quality of Life Outcomes and Tolerability of HUMIRA in Routine Clinical Use in Patients With RA PsA AS After Unsustainable Response to Disease Modifying Antirheumatic Drugs and or Biologicals.

Trial Profile

An Open Label Multicenter Post Marketing Observational Study for the Evaluation of Quality of Life Outcomes and Tolerability of HUMIRA in Routine Clinical Use in Patients With RA PsA AS After Unsustainable Response to Disease Modifying Antirheumatic Drugs and or Biologicals.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2011

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top